Recursion Pharmaceuticals, Inc. × Tempus AI, Inc.
Recursion Pharmaceuticals and Tempus AI amended and extended their data-sharing partnership, first established in 2023, through November 2029. [81] As part of the amendment signed on September 15, 2026, Recursion committed to pay Tempus $42 million over three years for continued access to Tempus's extensive real-world data library. [81, 84] This replaced a previous arrangement of potentially discretionary fees with committed payments. [81]
The asset
Extended license to access Tempus's library of de-identified, multimodal real-world clinical and molecular data.
The record
- Seller status
- Going concern
- Sector
- AI and precision medicine
- Modalities
- genomic, clinical, text
- Jurisdiction
- US
- Personal data
- de-identified
What it means if you hold data
This transaction highlights the increasing value of large-scale, multimodal data in drug discovery, establishing a clear multi-year, multi-million dollar price for access. The deal structure, converting discretionary fees into committed payments, signals a maturation of the data licensing market from exploratory partnerships to essential, budgeted R&D infrastructure.